Gyre Therapeutics (NASDAQ:GYRE) Stock Rating Lowered by Zacks Research

Gyre Therapeutics (NASDAQ:GYRE) was downgraded by analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a note issued to investors on Monday,Zacks.com reports.

GYRE has been the subject of several other research reports. Weiss Ratings restated a “sell (d)” rating on shares of Gyre Therapeutics in a research note on Thursday, January 22nd. Wall Street Zen downgraded Gyre Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, March 14th. Two analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $17.00.

Gyre Therapeutics Trading Down 8.4%

NASDAQ:GYRE opened at $7.01 on Monday. The firm has a market capitalization of $679.69 million, a PE ratio of 701.70 and a beta of 1.97. Gyre Therapeutics has a 1 year low of $6.11 and a 1 year high of $11.78. The firm’s fifty day simple moving average is $7.96 and its 200 day simple moving average is $7.77.

Gyre Therapeutics (NASDAQ:GYRE) last released its earnings results on Thursday, March 12th. The company reported $0.04 earnings per share for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.04). The firm had revenue of $37.20 million for the quarter, compared to analyst estimates of $36.30 million. Gyre Therapeutics had a return on equity of 10.85% and a net margin of 4.31%.

Institutional Trading of Gyre Therapeutics

Hedge funds have recently modified their holdings of the company. Bank of America Corp DE increased its position in shares of Gyre Therapeutics by 40.4% during the fourth quarter. Bank of America Corp DE now owns 6,937 shares of the company’s stock valued at $84,000 after purchasing an additional 1,996 shares during the period. Geode Capital Management LLC lifted its position in Gyre Therapeutics by 28.6% in the second quarter. Geode Capital Management LLC now owns 401,709 shares of the company’s stock worth $2,953,000 after purchasing an additional 89,390 shares during the period. JPMorgan Chase & Co. boosted its stake in Gyre Therapeutics by 84.6% during the second quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company’s stock worth $47,000 after buying an additional 2,961 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Gyre Therapeutics by 77.8% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company’s stock valued at $54,000 after buying an additional 3,244 shares during the period. Finally, State of Alaska Department of Revenue bought a new stake in Gyre Therapeutics in the 3rd quarter valued at $38,000. Institutional investors own 23.99% of the company’s stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.